Medical Care Technologies Inc. develops and commercializes artificial intelligence applications across consumer software, imaging analysis, healthcare-oriented pre-screening and collectibles authentication. News about MDCE centers on its AI technology stack, including Snapshot Recipes, a mobile recipe application with AI-generated food and beverage content, and Real Game Used, a subsidiary developing a patent-pending AI authentication platform for sports memorabilia.
Company updates also cover AI imaging initiatives for dermatological analysis, wellness monitoring, product verification and automated quality control, as well as capital and asset-monetization activity through Infinite Auctions. Recurring announcements describe product redesigns, commercialization pathways, subsidiary activity, mobile-app user growth initiatives, and enterprise API or visual analytics use cases.
Medical Care Technologies (MDCE) announced that subsidiary Real Game Used maintains a steady backlog of authentication work from customers and auction brands. The subsidiary recently launched an automated website submission system that lets customers initiate authentication requests online. Real Game Used remains an active revenue contributor within MDCE's broader operations.
Medical Care Technologies (MDCE) is working with task-based software technicians and external platforms to support technology and enterprise-services expansion. The work covers model refinement, integration, workflow development and platform scaling. Its first paid external software agreement is valued at up to $250,000. Subsidiaries Infinite Auctions and Real Game Used have also reached six figures in partnership activity within the arrangement's first few weeks.
Medical Care Technologies (MDCE) is expanding beyond AI software sales to provide businesses with AI model training and software integration consulting. Services include data preparation guidance, integration design and repeated model refinement.
The transition follows its first paid external software agreement, announced October 14, valued at up to $250,000 with a client group including current and retired NFL players. Subsidiaries Infinite Auctions and Real Game Used have also advanced a collectibles partnership that reached six figures in activity within its first few weeks.
Medical Care Technologies (MDCE) will post updated internal evaluation results for its Melanoma Scan Beta on its corporate website next week.
The update will cover a larger set of volunteer submissions, testing image intake and quality scoring, placement of images on a body map, and organization of successive images for visual review. First-pass testing showed that user photographs could move through those three stages. Volunteer intake remains open. The application remains in beta-stage development, has not received regulatory clearance, and is not a substitute for professional medical screening or evaluation.
Medical Care Technologies (MDCE) expects third-quarter 2026 revenue to exceed every trailing quarter over the last twelve months. The anticipated performance reflects initial revenue from its first paid external software agreement and sales through its subsidiaries' collectibles partnership. Full results are due in the coming weeks.
Full-year 2025 revenue rose 63% to $1,071,812 from $656,402 in 2024, while net income increased 53% to $230,768. Management anticipates further revenue growth in coming quarters and throughout 2027, without projecting specific results. Share issuance over the past year diluted holders; management is evaluating capital-structure steps intended to limit future dilution, but has announced no specific action.
Medical Care Technologies (MDCE) outlined commercialization plans following its first external enterprise software agreement, valued at up to $250,000.
The agreement was announced October 14, execution is underway, and the first payment has been initiated. The company is evaluating additional software opportunities. StrainScan Pro enterprise demonstrations continue as it works toward first enterprise clients. Subsidiaries Infinite Auctions and Real Game Used completed an initial six-figure game-worn memorabilia sale to Topps; additional supply discussions remain open. Melanoma Scan Beta and Wound Monitoring remain in development without regulatory clearance. The company expects another round of internal Melanoma Scan Beta evaluation results in the near term.
Medical Care Technologies (MDCE) entered its first paid external enterprise AI software agreement, with an initial value of $250,000. The multi-year agreement includes ongoing incentives, and the first payment has been initiated. The client group includes ambassadors who are current and former NFL athletes. This is the company's first paid external software engagement outside Snapshot Recipes.
A separate Topps/Fanatics sales agreement has surpassed the six-figure mark in the first month. MDCE Melanoma Scan Beta remains in active human-image testing; the company expects internal evaluation results to be posted on its website in the near term. Other application development and subsidiary operations remain separate from the software agreement.
Medical Care Technologies (MDCE) published internal technical evaluation results for its wound-monitoring application, which remains in development and continuous training.
Testing used controlled sequential smartphone captures. 84% met the internal image-usability threshold and advanced to comparison. On usable sequences, wound-boundary stability was 87%, with reduced drift versus the prior internal cycle when lighting and distance remained within the usable range. Alignment completed on 91% of multi-frame usable sequences for visual review over time.
These are technical workflow results, not clinical study results or evidence of clinical efficacy. The application has not received regulatory clearance and is not intended to diagnose or treat disease.
Medical Care Technologies (MDCE) continues accepting human-submitted images for internal testing of its Melanoma Scan Beta imaging and monitoring application.
Updated evaluation results are expected on the corporate website in the coming weeks. The September 29 first-pass results indicated that user photographs could pass through image-quality scoring, body-map registration and comparison over time. Additional submissions are intended to broaden testing across real-world photographic conditions.
The application remains in beta development and has not received regulatory clearance. Participation is internal technical evaluation, not a clinical efficacy trial or diagnosis program; the application is not a substitute for professional medical evaluation.
Medical Care Technologies (MDCE) plans to publish updated internal testing results for its wound-monitoring application on October 12, 2026.
The corporate website update is expected to cover image-quality scoring, wound-boundary identification and comparisons of images taken over time. The models remain in continuous training following the move into structured internal evaluation announced on September 28. The posting is intended as a technical progress report, not a product launch or clinical study result. The application remains in development and has not received regulatory clearance.